Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Jeff P. Sharman, Paulo Miranda, Jack Roos, Ugochinyere Emeribe, Ling Cai, Bengt Liljas & Priyanka Gaitonde. (2023) Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia. Leukemia & Lymphoma 64:7, pages 1243-1252.
Read now
Read now
Evan W Davies, Samuel Llewellyn, Amélie Beaudet, Charlotte E Kosmas, Wendy Gin-Sing & Helen A Doll. (2018) Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension. Patient Preference and Adherence 12, pages 1079-1088.
Read now
Read now
Moushmi Singh, Stuart Mealing, Simona Baculea, Sarah Cote & Jo Whelan. (2017) Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy. Journal of Medical Economics 20:10, pages 1066-1073.
Read now
Read now
Luis Felipe Casado, Amparo Burgos, Eva González-Haba, Javier Loscertales, Tania Krivasi, Javier Orofino, Carlos Rubio-Terres & Darío Rubio-Rodríguez. (2016) Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain. ClinicoEconomics and Outcomes Research 8, pages 475-484.
Read now
Read now
Articles from other publishers (14)
Yuan Hong, Xichuang Chen, Yuanquan Hong, Xingfang Xiao, Yan Wang, Xiaohong You, Jingyi Mi, Tao Zhou, Panpan Zheng & Zhihu Huang. (2023) Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study. BMC Health Services Research 23:1.
Crossref
Crossref
Soroush Fariman, Fatemeh Momeni Nasab, Hoda Faraji & Monireh Afzali. (2023) Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran. Value in Health Regional Issues 38, pages 93-100.
Crossref
Crossref
Martin Vu, Koen Degeling, Ella R. Thompson, Piers Blombery, David Westerman & Maarten J. IJzerman. (2023) Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia. Applied Health Economics and Health Policy.
Crossref
Crossref
Matilde Slot, Carsten Utoft Niemann, Lars Holger Ehlers & Emelie Curovic Rotbain. (2023)
Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without
TP53
aberrations
. Blood Advances 7:15, pages 4186-4196.
Crossref
Crossref
Neda Alrawashdh, Ali McBride, Brian Erstad, Joann Sweasy, Daniel O. Persky & Ivo Abraham. (2022) Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia. Value in Health 25:10, pages 1685-1695.
Crossref
Crossref
Siu Hing Lo, Andrew Lloyd, Shuayb Elkhalifa, Zlatko Sisic & Floortje E. van Nooten. (2021) Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States. PharmacoEconomics - Open 6:2, pages 231-239.
Crossref
Crossref
Siu Hing Lo, Jade Marshall, Hanna Skrobanski & Andrew Lloyd. (2021) Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex. PharmacoEconomics - Open 6:1, pages 105-121.
Crossref
Crossref
Kishan K. PatelIris IsufiShalin KothariAmy J. Davidoff, Cary P. Gross & Scott F. Huntington. (2020) Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 136:17, pages 1946-1955.
Crossref
Crossref
James I. Barnes, Vasu DiviAdrian BegayeRussell Wong, Steven Coutre, Douglas K. OwensJeremy D. Goldhaber-Fiebert. (2018) Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Advances 2:15, pages 1946-1956.
Crossref
Crossref
Richa Sinha & William Ken Redekop. (2018) Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom. Clinical Lymphoma Myeloma and Leukemia 18:2, pages e131-e142.
Crossref
Crossref
Ana Teresa Paquete, Luís Silva Miguel, Ursula Becker, Catarina Pereira & Carlos Gouveia Pinto. (2017) Cost‐Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy. Applied Health Economics and Health Policy 15:4, pages 501-512.
Crossref
Crossref
Ruben A. Mesa, Carole B. Miller, Maureen Thyne, James Mangan, Sara Goldberger, Salman Fazal, Xiaomei Ma, Wendy Wilson, Dilan C. Paranagama, David G. Dubinski, Ahmad Naim, Shreekant Parasuraman, John Boyle & John O. Mascarenhas. (2017) Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Cancer 123:3, pages 449-458.
Crossref
Crossref
Ursula Becker, Andrew H. Briggs, Santiago G. Moreno, Joshua A. Ray, Phuong Ngo & Kunal Samanta. (2016) Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy. Value in Health 19:4, pages 374-382.
Crossref
Crossref
Erkki Soini, Anne Hautala, Eira Poikonen, Ursula Becker, Mira Kyttälä & Janne Martikainen. (2016) Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable. Clinical Therapeutics 38:4, pages 889-904.e14.
Crossref
Crossref